Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors
Abstract
:1. Introduction
2. Adenovirus vector types based on human adenovirus type five
3. Immune responses to Ad vectors
4. Vector genome modifications to dampen immune responses
5. Chemical shielding to reduce unwanted surface interactions
6. Exploiting adenoviral immunogenicity in vaccine development
7. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Reddy, V.S.; Natchiar, S.K.; Stewart, P.L.; Nemerow, G.R. Crystal structure of human adenovirus at 3.5 A resolution. Science 2010, 329, 1071–1075. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, H.; Jin, L.; Koh, S.B.S.; Atanasov, I.; Schein, S.; Wu, L. Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks. Science 2010, 329, 1038–1043. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pearson, S.; Jia, H.; Kandachi, K. China approves first gene therapy. Nat. Biotechnol. 2004, 22, 3–4. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Nunes, F.A.; Berencsi, K.; Furth, E.E.; Gönczöl, E.; Wilson, J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 1994, 91, 4407–4411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, Y.; Ertl, H.C.; Wilson, J.M. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994, 1, 433–442. [Google Scholar] [CrossRef]
- Amalfitano, A.; Hauser, M.A.; Hu, H.; Serra, D.; Begy, C.R.; Chamberlain, J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. 1998, 72, 926–933. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Engelhardt, J.F.; Ye, X.; Doranz, B.; Wilson, J.M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 1994, 91, 6196–6200. [Google Scholar] [CrossRef] [Green Version]
- Gao, G.P.; Yang, Y.; Wilson, J.M. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 1996, 70, 8934–8943. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Q.; Greenburg, G.; Bunch, D.; Farson, D.; Finer, M.H. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Gene Ther. 1997, 4, 393–400. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Armentano, D.; Zabner, J.; Sacks, C.; Sookdeo, C.C.; Smith, M.P.; St George, J.A. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 1997, 71, 2408–2416. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rosewell, A.; Vetrini, F.; Ng, P. Helper-Dependent Adenoviral Vectors. J. Genet. Syndr. Gene Ther. 2011. [Google Scholar] [CrossRef] [Green Version]
- Raper, S.E.; Chirmule, N.; Lee, F.S.; Wivel, N.A.; Bagg, A.; Gao, G. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003, 80, 148–158. [Google Scholar] [CrossRef] [PubMed]
- Alemany, R.; Suzuki, K.; Curiel, D.T. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 2000, 81, 2605–2609. [Google Scholar] [CrossRef]
- Muruve, D.A.; Barnes, M.J.; Stillman, I.E.; Libermann, T.A. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 1999, 10, 965–976. [Google Scholar] [CrossRef] [PubMed]
- Schnell, M.A.; Zhang, Y.; Tazelaar, J.; Gao, G.P.; Yu, Q.C.; Qian, R. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. J. Am. Soc. Gene Ther. 2001, 3, 708–722. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Chirmule, N.; Gao, G.P.; Qian, R.; Croyle, M.; Joshi, B. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. J. Am. Soc. Gene Ther. 2001, 3, 697–707. [Google Scholar] [CrossRef]
- Lieber, A.; He, C.Y.; Meuse, L.; Schowalter, D.; Kirillova, I.; Winther, B. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 1997, 71, 8798–8807. [Google Scholar] [CrossRef] [Green Version]
- Borgland, S.L.; Bowen, G.P.; Wong, N.C.; Libermann, T.A.; Muruve, D.A. Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB. J. Virol. 2000, 74, 3941–3947. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bowen, G.P.; Borgland, S.L.; Lam, M.; Libermann, T.A.; Wong, N.C.W.; Muruve, D.A. Adenovirus vector-induced inflammation: Capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B. Hum. Gene Ther. 2002, 13, 367–379. [Google Scholar] [CrossRef] [PubMed]
- Reid, T.; Galanis, E.; Abbruzzese, J.; Sze, D.; Andrews, J.; Romel, L. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther. 2001, 8, 1618–1626. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reid, T.; Galanis, E.; Abbruzzese, J.; Sze, D.; Wein, L.M.; Andrews, J. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002, 62, 6070–6079. [Google Scholar] [PubMed]
- Ben-Gary, H.; McKinney, R.L.; Rosengart, T.; Lesser, M.L.; Crystal, R.G. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol. Ther. J. Am. Soc. Gene Ther. 2002, 6, 287–297. [Google Scholar]
- Brunetti-Pierri, N.; Palmer, D.J.; Beaudet, A.L.; Carey, K.D.; Finegold, M.; Ng, P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther. 2004, 15, 35–46. [Google Scholar] [CrossRef]
- Kiang, A.; Hartman, Z.C.; Everett, R.S.; Serra, D.; Jiang, H.; Frank, M.M. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol. Ther. J. Am. Soc. Gene Ther. 2006, 14, 588–598. [Google Scholar] [CrossRef] [PubMed]
- Cichon, G.; Boeckh-Herwig, S.; Kuemin, D.; Hoffmann, C.; Schmidt, H.H.; Wehnes, E. Titer determination of Ad5 in blood: A cautionary note. Gene Ther. 2003, 10, 1012–1017. [Google Scholar] [CrossRef]
- Jiang, H.; Wang, Z.; Serra, D.; Frank, M.M.; Amalfitano, A. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol. Ther. J. Am. Soc. Gene Ther. 2004, 10, 1140–1142. [Google Scholar] [CrossRef]
- Xu, Z.; Qiu, Q.; Tian, J.; Smith, J.S.; Conenello, G.M.; Morita, T. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat. Med. 2013, 19, 452–457. [Google Scholar] [CrossRef]
- Abbink, P.; Lemckert, A.A.C.; Ewald, B.A.; Lynch, D.M.; Denholtz, M.; Smits, S. Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D. J. Virol. 2007, 81, 4654–4663. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schmitz, H.; Wigand, R.; Heinrich, W. Worldwide epidemiology of human adenovirus infections. Am. J. Epidemiol. 1983, 117, 455–466. [Google Scholar] [CrossRef]
- Benevento, M.; Di Palma, S.; Snijder, J.; Moyer, C.L.; Reddy, V.S.; Nemerow, G.R. Adenovirus composition, proteolysis, and disassembly studied by in-depth qualitative and quantitative proteomics. J. Biol. Chem. 2014, 289, 11421–11430. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rux, J.J.; Kuser, P.R.; Burnett, R.M. Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J. Virol. 2003, 77, 9553–9566. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Toogood, C.I.; Crompton, J.; Hay, R.T. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J. Gen. Virol. 1992, 73, 1429–1435. [Google Scholar] [CrossRef]
- Bradley, R.R.; Lynch, D.M.; Iampietro, M.J.; Borducchi, E.N.; Barouch, D.H. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J. Virol. 2012, 86, 625–629. [Google Scholar] [CrossRef] [Green Version]
- Qiu, H.; Li, X.; Tian, X.; Zhou, Z.; Xing, K.; Li, H. Serotype-Specific Neutralizing Antibody Epitopes of Human Adenovirus Type 3 (HAdV-3) and HAdV-7 Reside in Multiple Hexon Hypervariable Regions. J. Virol. 2012, 86, 7964–7975. [Google Scholar] [CrossRef] [Green Version]
- Sumida, S.M.; Truitt, D.M.; Lemckert, A.A.C.; Vogels, R.; Custers, J.H.H.V.; Addo, M.M. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. Baltim. Md. 2005, 174, 7179–7185. [Google Scholar] [CrossRef] [Green Version]
- Hong, S.S.; Habib, N.A.; Franqueville, L.; Jensen, S.; Boulanger, P.A. Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J. Virol. 2003, 77, 10366–10375. [Google Scholar] [CrossRef] [Green Version]
- Zak, D.E.; Andersen-Nissen, E.; Peterson, E.R.; Sato, A.; Hamilton, M.K.; Borgerding, J. Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc. Natl. Acad. Sci. USA 2012, 109, E3503–E3512. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Varnavski, A.N.; Zhang, Y.; Schnell, M.; Tazelaar, J.; Louboutin, J.-P.; Yu, Q.-C. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J. Virol. 2002, 76, 5711–5719. [Google Scholar] [CrossRef] [Green Version]
- Varnavski, A.N.; Calcedo, R.; Bove, M.; Gao, G.; Wilson, J.M. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther. 2005, 12, 427–436. [Google Scholar] [CrossRef] [Green Version]
- Perreau, M.; Pantaleo, G.; Kremer, E.J. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J. Exp. Med. 2008, 205, 2717–2725. [Google Scholar] [CrossRef] [PubMed]
- Cotter, M.J.; Zaiss, A.K.; Muruve, D.A. Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J. Virol. 2005, 79, 14622–14631. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zaiss, A.K.; Vilaysane, A.; Cotter, M.J.; Clark, S.A.; Meijndert, H.C.; Colarusso, P. Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response. J. Immunol. Baltim. Md. 2009, 182, 7058–7068. [Google Scholar] [CrossRef] [Green Version]
- Tang, J.; Olive, M.; Pulmanausahakul, R.; Schnell, M.; Flomenberg, N.; Eisenlohr, L. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology 2006, 350, 312–322. [Google Scholar] [CrossRef] [Green Version]
- Sumida, S.M.; Truitt, D.M.; Kishko, M.G.; Arthur, J.C.; Jackson, S.S.; Gorgone, D.A. Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors. J. Virol. 2004, 78, 2666–2673. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Olive, M.; Eisenlohr, L.; Flomenberg, N.; Hsu, S.; Flomenberg, P. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum. Gene Ther. 2002, 13, 1167–1178. [Google Scholar] [CrossRef]
- Bett, A.J.; Prevec, L.; Graham, F.L. Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 1993, 67, 5911–5921. [Google Scholar] [CrossRef] [Green Version]
- Parks, R.J.; Graham, F.L. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J. Virol. 1997, 71, 3293–3298. [Google Scholar] [CrossRef] [Green Version]
- Parks, R.J.; Bramson, J.L.; Wan, Y.; Addison, C.L.; Graham, F.L. Effects of Stuffer DNA on Transgene Expression from Helper-Dependent Adenovirus Vectors. J. Virol. 1999, 73, 8027–8034. [Google Scholar] [CrossRef] [Green Version]
- Aderem, A.; Ulevitch, R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406, 782–787. [Google Scholar] [CrossRef]
- Hoebe, K.; Janssen, E.; Beutler, B. The interface between innate and adaptive immunity. Nat. Immunol. 2004, 5, 971–974. [Google Scholar] [CrossRef] [PubMed]
- Kawai, T.; Akira, S. Innate immune recognition of viral infection. Nat. Immunol. 2006, 7, 131–137. [Google Scholar] [CrossRef]
- Ahmad-Nejad, P.; Häcker, H.; Rutz, M.; Bauer, S.; Vabulas, R.M.; Wagner, H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 2002, 32, 1958–1968. [Google Scholar] [CrossRef]
- Latz, E.; Schoenemeyer, A.; Visintin, A.; Fitzgerald, K.A.; Monks, B.G.; Knetter, C.F. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 2004, 5, 190–198. [Google Scholar] [CrossRef]
- Cerullo, V.; Seiler, M.P.; Mane, V.; Brunetti-Pierri, N.; Clarke, C.; Bertin, T.K. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol. Ther. J. Am. Soc. Gene Ther. 2007, 15, 378–385. [Google Scholar] [CrossRef] [PubMed]
- Kim, I.H.; Józkowicz, A.; Piedra, P.A.; Oka, K.; Chan, L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc. Natl. Acad. Sci. USA 2001, 98, 13282–13287. [Google Scholar] [CrossRef] [Green Version]
- Toietta, G.; Mane, V.P.; Norona, W.S.; Finegold, M.J.; Ng, P.; McDonagh, A.F. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc. Natl. Acad. Sci. USA 2005, 102, 3930–3935. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morral, N.; O’Neal, W.; Rice, K.; Leland, M.; Kaplan, J.; Piedra, P.A. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA 1999, 96, 12816–12821. [Google Scholar] [CrossRef] [Green Version]
- Brunetti-Pierri, N.; Ng, T.; Iannitti, D.; Cioffi, W.; Stapleton, G.; Law, M. Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors. Hum. Gene Ther. 2013, 24, 761–765. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muruve, D.A.; Cotter, M.J.; Zaiss, A.K.; White, L.R.; Liu, Q.; Chan, T. Helper-Dependent Adenovirus Vectors Elicit Intact Innate but Attenuated Adaptive Host Immune Responses In Vivo. J. Virol. 2004, 78, 5966–5972. [Google Scholar] [CrossRef] [Green Version]
- Delgado, C.; Francis, G.E.; Fisher, D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carr. Syst. 1992, 9, 249–304. [Google Scholar]
- Parveen, S.; Sahoo, S.K. Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs. Clin. Pharmacokinet. 2006, 45, 965–988. [Google Scholar] [CrossRef] [PubMed]
- Fisher, K.D.; Stallwood, Y.; Green, N.K.; Ulbrich, K.; Mautner, V.; Seymour, L.W. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001, 8, 341–348. [Google Scholar] [CrossRef] [Green Version]
- O’Riordan, C.R.; Lachapelle, A.; Delgado, C.; Parkes, V.; Wadsworth, S.C.; Smith, A.E. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 1999, 10, 1349–1358. [Google Scholar] [CrossRef]
- Croyle, M.A.; Chirmule, N.; Zhang, Y.; Wilson, J.M. Stealth adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 2001, 75, 4792–4801. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Croyle, M.A.; Chirmule, N.; Zhang, Y.; Wilson, J.M. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 2002, 13, 1887–1900. [Google Scholar] [CrossRef]
- Mok, H.; Palmer, D.J.; Ng, P.; Barry, M.A. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. J. Am. Soc. Gene Ther. 2005, 11, 66–79. [Google Scholar] [CrossRef]
- Subr, V.; Kostka, L.; Selby-Milic, T.; Fisher, K.; Ulbrich, K.; Seymour, L.W. Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J. Control Release Off. J. Control Release Soc. 2009, 135, 152–158. [Google Scholar] [CrossRef] [PubMed]
- Green, N.K.; Herbert, C.W.; Hale, S.J.; Hale, A.B.; Mautner, V.; Harkins, R. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004, 11, 1256–1263. [Google Scholar] [CrossRef]
- Kreppel, F.; Gackowski, J.; Schmidt, E.; Kochanek, S. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol. Ther. J. Am. Soc. Gene Ther. 2005, 12, 107–117. [Google Scholar] [CrossRef]
- Corjon, S.; Wortmann, A.; Engler, T.; van Rooijen, N.; Kochanek, S.; Kreppel, F. Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere. Mol. Ther. J. Am. Soc. Gene Ther. 2008, 16, 1813–1824. [Google Scholar] [CrossRef] [PubMed]
- Prill, J.-M.; Espenlaub, S.; Samen, U.; Engler, T.; Schmidt, E.; Vetrini, F. Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol. Ther. J. Am. Soc. Gene Ther. 2011, 19, 83–92. [Google Scholar] [CrossRef] [Green Version]
- Krutzke, L.; Prill, J.M.; Engler, T.; Schmidt, C.Q.; Xu, Z.; Byrnes, A.P. Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity. J. Control Release Off. J. Control Release Soc. 2016, 235, 379–392. [Google Scholar] [CrossRef] [Green Version]
- Khare, R.; Reddy, V.S.; Nemerow, G.R.; Barry, M.A. Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. J. Virol. 2012, 86, 2293–2301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prill, J.-M.; Subr, V.; Pasquarelli, N.; Engler, T.; Hoffmeister, A.; Kochanek, S. Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo. PLoS ONE 2014, 9, e82716. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schmid, M.; Ernst, P.; Honegger, A.; Suomalainen, M.; Zimmermann, M.; Braun, L. Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. Nat. Commun. 2018, 9, 450. [Google Scholar] [CrossRef]
- Campos, S.K.; Barry, M.A. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 2006, 349, 453–462. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Espenlaub, S.; Corjon, S.; Engler, T.; Fella, C.; Ogris, M.; Wagner, E. Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications. Hum. Gene Ther. 2010, 21, 1155–1167. [Google Scholar] [CrossRef] [PubMed]
- Zhang, C.; Zhou, D. Adenoviral vector-based strategies against infectious disease and cancer. Hum. Vaccines Immunother. 2016, 12, 2064–2074. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Folegatti, P.M.; Ewer, K.J.; Aley, P.K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020, 396, 467–478. [Google Scholar] [CrossRef]
- Zhu, F.-C.; Guan, X.-H.; Li, Y.-H.; Huang, J.-Y.; Jiang, T.; Hou, L.-H. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020, 396, 479–488. [Google Scholar] [CrossRef]
- Logunov, D.Y.; Dolzhikova, I.V.; Zubkova, O.V.; Tukhvatulin, A.I.; Shcheblyakov, D.V.; Dzharullaeva, A.S. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet Lond. Engl. 2020, 396, 887–897. [Google Scholar] [CrossRef]
- Logunov, D.Y.; Dolzhikova, I.V.; Shcheblyakov, D.V.; Tukhvatulin, A.I.; Zubkova, O.V.; Dzharullaeva, A.S. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet Lond. Engl. 2021, 397, 671–681. [Google Scholar] [CrossRef]
- Ramasamy, M.N.; Minassian, A.M.; Ewer, K.J.; Flaxman, A.L.; Folegatti, P.M.; Owens, D.R. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet Lond. Engl. 2021, 396, 1979–1993. [Google Scholar] [CrossRef]
- Tripathy, S.K.; Black, H.B.; Goldwasser, E.; Leiden, J.M. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 1996, 2, 545–550. [Google Scholar] [CrossRef]
- Yang, Y.; Su, Q.; Wilson, J.M. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J. Virol. 1996, 70, 7209–7212. [Google Scholar] [CrossRef] [Green Version]
- Harui, A.; Roth, M.D.; Kiertscher, S.M.; Mitani, K.; Basak, S.K. Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL. Gene Ther. 2004, 11, 1617–1626. [Google Scholar] [CrossRef] [PubMed]
- Schirmbeck, R.; Reimann, J.; Kochanek, S.; Kreppel, F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol. Ther. J. Am. Soc. Gene Ther. 2008, 16, 1609–1616. [Google Scholar] [CrossRef]
- Weaver, E.A.; Nehete, P.N.; Buchl, S.S.; Senac, J.S.; Palmer, D.; Ng, P. Comparison of Replication-Competent, First Generation, and Helper-Dependent Adenoviral Vaccines. PLoS ONE 2009, 4, e5059. [Google Scholar] [CrossRef] [PubMed]
- Kron, M.W.; Engler, T.; Schmidt, E.; Schirmbeck, R.; Kochanek, S.; Kreppel, F. High-capacity adenoviral vectors circumvent the limitations of ΔE1 and ΔE1/ΔE3 adenovirus vectors to induce multispecific transgene product-directed CD8 T-cell responses. J. Gene Med. 2011, 13, 648–657. [Google Scholar] [CrossRef]
- Wortmann, A.; Vöhringer, S.; Engler, T.; Corjon, S.; Schirmbeck, R.; Reimann, J. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. J. Am. Soc. Gene Ther. 2008, 16, 154–162. [Google Scholar] [CrossRef]
- Weaver, E.A.; Barry, M.A. Effects of Shielding Adenoviral Vectors with Polyethylene Glycol on Vector-Specific and Vaccine-Mediated Immune Responses. Hum. Gene Ther. 2008, 19, 1369–1382. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kreppel, F.; Hagedorn, C. Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. Int. J. Mol. Sci. 2021, 22, 2417. https://doi.org/10.3390/ijms22052417
Kreppel F, Hagedorn C. Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. International Journal of Molecular Sciences. 2021; 22(5):2417. https://doi.org/10.3390/ijms22052417
Chicago/Turabian StyleKreppel, Florian, and Claudia Hagedorn. 2021. "Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors" International Journal of Molecular Sciences 22, no. 5: 2417. https://doi.org/10.3390/ijms22052417